JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
:2126
Want to see HK:2126 full AI Analyst Report?
2126 Stock Chart & Stats
HK$2.50
-HK$0.02(-1.56%)
At close: 4:00 PM EST
HK$2.50
-HK$0.02(-1.56%)
Day’s Range― - ―
52-Week RangeHK$1.66 - HK$6.44
Previous CloseN/A
Volume104.00K
Average Volume (3M)2.67M
Market Cap
HK$858.46M
Enterprise ValueHK$507.69M
Total Cash (Recent Filing)HK$503.28M
Total Debt (Recent Filing)HK$262.67M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding416,729,430
10 Day Avg. Volume1,852,649
30 Day Avg. Volume2,667,300
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.68
Price to Sales (P/S)3.39
P/FCF Ratio-11.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)HK$312.38M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin RecoveryA 55% revenue rebound with gross margin rising to ~43% indicates renewed commercial traction and improved unit economics. Durable top-line and margin gains support reinvestment capacity, reduce the distance to break-even, and improve the likelihood of sustainable cash generation over months.
Manageable LeverageDebt-to-equity around 0.47 signals limited reliance on leverage versus equity, lowering near-term refinancing risk. For an R&D-heavy biotech, manageable leverage preserves flexibility to fund trials and commercialization without acute solvency pressure, supporting strategic options over the medium term.
Material Improvement In Operating Cash FlowA large reduction in operating cash burn (-77M vs -333M) reflects improved cost control or working-capital dynamics. This durable improvement lowers near-term external funding needs and shows management can tighten cash conversion, increasing runway if the trend persists over subsequent quarters.
Bears Say
Deep And Persistent UnprofitabilityNet margin near -196% and materially negative EBIT/EBITDA indicate the business is far from operational break-even. Sustained heavy losses erode cash reserves and restrict ability to self-fund R&D and commercialization, requiring ongoing capital raises that weigh on long-term shareholder value.
Ongoing Negative Free Cash FlowConsistent negative free cash flow means the company must repeatedly access external capital. Over a multi-month horizon, that reliance raises financing risk, can force dilutive equity issuances or costly debt, and limits strategic flexibility versus peers that generate positive cash flow.
Erosion Of Equity / Capital BaseMaterial decline in equity from prior years shows cumulative losses have weakened the capital buffer. A shrunken equity base heightens vulnerability to setbacks, increases the potential dilutive impact of future financings, and makes recovery more dependent on sustained profit or capital injections.
JW (Cayman) Therapeutics Co. Ltd. News
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.66 and its highest was HK$6.44 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$858.46M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 102 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.758 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.758.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,729,430 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.758 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.124%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.33%
12-Months-Change
Fundamentals
Return on Equity
-75.15%
Trailing 12-Months
Asset Growth
-38.53%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Lepu Biopharma Co. Ltd. Class H
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---